Adverse Event Analysis and MedDRA: Business as Usual or Challenge? *

Abstract

The Medical Dictionary for Regulatory Activities (MedDRA) is a dictionary of medical terms which covers signs and symptoms; diseases; diagnoses; therapeutic indications; names and qualitative results of indications; surgical and medical procedures; and medical, social, and family history. Until now, the pharmaceutical industry was only obligated to use MedDRA for submissions of individual case safety reports. Neither the MedDRA Maintenance and Support Services Organization nor regulatory bodies provided any recommendations on the use of MedDRA for analyses and reporting of clinical trial data. As the pharmaceutical industry introduces MedDRA in its day-to-day processes, there is an urgent need to fill this gap. The Biometry Subgroup of the German Association of Research-Based Pharmaceutical Companies has established a working group which will provide recommendations on the use of MedDRA in reporting and labeling. This paper aims to start a discussion about the use of MedDRA in the analysis of clinical trials.

Keywords

MedDRA Adverse events Safety analysis Clinical trials

Get full access to this article

View all access options for this article.

References

MedDRA Maintenance and Support Services Organization. http://www.meddramsso.com. Accessed July 1, 2003.

U.S. Food and Drug Administration. Guidance for Industry. Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines. http://www.fda.gov/cder/guidance/4177dft.pdf. Accessed July 1, 2003.

Doan

TVT

. Converting legacy data to MedDRA: Approach and implications. Drug Inf J. 2002; 36(3):659–666.

MedDRA Introductory Guide v5.1. Reston, VA: MedDRA Maintenance and Support Services Organization; September 2002. MSSO-D1–6003-5.1.0.

International Conference on Harmonisation. MedDRA® Term Selection: Points to Consider. ICH-Endorsed Guide for MedDRA Users, Release 3.1. Basel, Switzerland: International Conference on Harmonisation; 2002.

MedDRA Maintenance and Support Services Organization. The MedDRA® MSSO Recommendations for MedDRA Implementation and Versioning for Clinical Trials. http://www.meddramsso.com/newwebaug2001/meddramsso/whatsnew/pdfFiles/clinicaltrialversioning.pdf. Accessed July 1, 2003.

Brosch

Minutes of the MedDRA® MSSO International User Group Meeting, Chicago, Illinois, June 20, 2002. http://www.meddramsso.com/newwebaug2001/meddramsso/resources/archive_usrmtg.htm. Accessed July 1, 2003.

CFR Parts 310, 312, et al. Safety Reporting Requirements for Human Drug and Biological Products; Proposed Rule. http://www.fda.gov/OHRMS/DOCKETS/98fr/03-5204.pdf. Accessed July 1, 2003.

ICH E3: Structure and Content of Clinical Study Reports. http://www.fda.gov/cder/guidance/iche3.pdf. Accessed July 1, 2003.

10.

ICH The Common Technical Document for the Registration of Pharmaceuticals for Human Use Efficacy—M4E; Clinical Overview and Clinical Summary of Module 2; Modules: Clinical Study Reports. http://www.fda.gov/cder/guidance/4539E.pdf. Accessed July 1, 2003.

11.

Tremmel

Scarpone

. Using MedDRA for adverse events in cancer trials: Experience, caveats, and advice. Drug Inf J. 2001; 35(3):845–852.

12.

Brown

. Effects of coding dictionary on signal generation. A consideration of use MedDRA compared with WHO-ART. Drug Safety. 2002; 25(6):445–452.

13.

Mozzicato

. MAGs: a new—and improved—way of thinking. MedDRA Messenger. 2002; September, 2.

14.

MedDRA Maintenance and Support Services Organization. Standardized MedDRA Queries. http://www.meddramsso.com/newwebaug2001/meddramsso/meddra/smq.htm. Accessed July 1, 2003.

15.

Kim

Goldberg

. The effect of outcome mis-classification and measurement error on the design and analysis of therapeutic equivalence trials. Stat Med. 2001;20, 2065–2078.